Annals of Clinical and Analytical Medicine 513 Annals of Clinical and Analytical Medicine Original Research Fatih Selvi, Cihan Bedel, Mustafa Korkut, Ökkeş Zortuk Department of Emergency Medicine, Health Science University, Antalya Training and Research Hospital, Antalya, Turkey Immature granulocytes in coronavirus disease 2019 (COVID‑19) Can immature granulocytes predict mortality in coronavirus disease 2019 (COVID‑19) infection in patients with chronic kidney disease? DOI: 10.4328/ACAM.20719 Received: 2021‑05‑29 Accepted: 2021‑08‑19 Published Online: 2021‑09‑12 Printed: 2021‑09‑15 Ann Clin Anal Med 2021;12(Suppl 4): S513‑517 Corresponding Author: Cihan Bedel, Health Science University, Antalya Training And Research Hospital, Kazım Karabekir Street, postal zip code: 07100, Muratpaşa, Antalya, Turkey. E‑mail: cihanbedel@hotmail.com P: +90 507 564 12 54 F: +90 242 249 44 87 Corresponding Author ORCID ID: https://orcid.org/0000‑0002‑3823‑2929 Abstract Aim: The association between mortality and comorbid diseases such as cardiovascular disease, chronic kidney disease (CKD), diabetes, and other chronic diseases has been reported in COVID-19 patients. Mortality is 14-16 times higher in patients with CKD. Infammation plays an important role in the pathophysiology of COVID‑19. Immature granulocytes (IG%) are used to make an immediate diagnosis in cases of severe infections. Therefore, we aimed to investigate whether IG% can be used as a prognostic factor in CKD patients who have contracted COVID‑19. Material and Methods: All CKD patients admitted to our center in the period between June and December 2020 with a COVID‑19 diagnosis were reviewed. Complete blood count and biochemical tests were performed and the results were recorded. According to the occurrence of in‑hospital mortality, the patients were categorized into groups and intergroup comparisons were conducted. Results: Our study included 87 patients, 42 (48.3%) of whom were women. The mean age of the patients was 67.07±13.52 years. Of the patients included in the study, 71 (81.6%) were survivors and 16 (18.4%) were non‑survivors. The comparison of the mean IG% between the survivor and non‑survivor groups did not reveal a signifcant correlation (0.72±0.52 vs. 0.71±0.42; p=0.754). The comparison of disease severity between the groups with high and normal IG% did not reveal a signifcant diference (24.4% vs. 21.1%; p=0.769). Discussion: IG% cannot be used as an indicator to predict mortality in CKD patients with COVID‑19. Keywords Coronavirus Disease 2019, Chronic Kidney Disease, Mortality, Immature Granulocytes